---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-118700"
form_type: "8-K"
ticker: null
cik: "0001124140"
company_name: "EXACT SCIENCES CORP"
filed_at: "2026-03-23T23:59:59+00:00"
generated_at: "2026-05-15T09:19:53.734149+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Abbott completes acquisition of Exact Sciences for $105/share cash, ~$21B

## Summary
- Merger effective March 23, 2026; each Exact share converted into $105.00 cash without interest.
- Total merger consideration approximately $21 billion, funded via cash on hand and debt.
- All Exact directors resigned at effective time; officers ceased positions.
- Outstanding options, RSUs, and performance units cashed out or assumed by Abbott.
- Exact's convertible notes now convertible solely into cash based on $105 conversion rate; stock delisted from Nasdaq.

## SEC filing metadata
- accession: 0001193125-26-118700
- form_type: 8-K
- cik: 0001124140
- company_name: EXACT SCIENCES CORP
- filed_at: 2026-03-23T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1124140/000119312526118700/0001193125-26-118700-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1124140/000119312526118700/d128802d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-118700
- JSON: https://secwatch.observer/filing/0001193125-26-118700.json
- Plain text: https://secwatch.observer/filing/0001193125-26-118700.txt

## Source-grounded claims
- claim_id: e2dbac397b2999660eb84be48f0e05c8d7fd778b
  claim: EXACT SCIENCES CORP: Bylaws amended and restated in their entirety.
  evidence_excerpt: At the Effective Time, the certificate of incorporation and bylaws of Exact were each amended and restated in their entirety as set forth in Exhibit 3.1 and Exhibit 3.2, respectively, to this Current Report on Form 8-K
  evidence_url: https://www.sec.gov/Archives/edgar/data/1124140/000119312526118700/0001193125-26-118700-index.htm
- claim_id: f9d2331527b065fae023b7b29a44b8b383aa4a95
  claim: EXACT SCIENCES CORP: Certificate of incorporation amended and restated in its entirety.
  evidence_excerpt: At the Effective Time, the certificate of incorporation and bylaws of Exact were each amended and restated in their entirety as set forth in Exhibit 3.1 and Exhibit 3.2, respectively, to this Current Report on Form 8-K
  evidence_url: https://www.sec.gov/Archives/edgar/data/1124140/000119312526118700/0001193125-26-118700-index.htm
- claim_id: 0e301344f33581f126a404fc3bb122ee1b165f2d
  claim: EXACT SCIENCES CORP underwent a change of control involving Abbott Laboratories for $105.00 in cash (closed 2026-03-23).
  evidence_excerpt: xchange Commission (the “ SEC ”) on November 20, 2025 (the “ Initial 8 -K ”), by Exact Sciences Corporation, a Delaware corporation (“ Exact ”), Exact entered into an Agreement and Plan of Merger, dated as of November 19, 2025 (the “ Merger Agreement ”), with Abbott Laboratories, an Illinois corporation (“ Abbott ”), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Abbott (“ Merger Sub ”), providing for the merger of Merger Sub with and into Exact (the “ Merger ”), with Exact surviving the Merger as a direct, wholly owned subsidiary of Abbott.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1124140/000119312526118700/0001193125-26-118700-index.htm
- claim_id: 20c85222e09e87d5e9a716906e92e35d7e1b3499
  claim: EXACT SCIENCES CORP terminated Credit Agreement with JPMorgan Chase Bank, N.A. (effective 2026-03-23).
  evidence_excerpt: On March 23, 2026, Exact repaid in full any outstanding principal and paid any accrued and unpaid interest (together with all fees, expenses and other amounts owed in connection therewith), and effectuated the release of all liens securing any obligations and the release of all guarantees, under the Credit Agreement, dated as of January 13, 2025, among Exact, the lenders from time to time party thereto, and JPMorgan Chase Bank, N.A., as administrative agent.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1124140/000119312526118700/0001193125-26-118700-index.htm
- claim_id: f538f0b2d5e3d0e22c9d410c453ad2a6873116c8
  claim: EXACT SCIENCES CORP amended Supplemental Indentures with U.S. Bank Trust Company, National Association (effective 2026-03-23).
  evidence_excerpt: On March 23, 2026, Exact and U.S. Bank Trust Company, National Association (as successor to U.S. Bank National Association), as trustee (the “ Trustee ”), entered into the Sixth Supplemental Indenture with respect to the 2027 Notes (the “ 2027 Supplemental Indenture ”), the Seventh Supplemental Indenture with respect to the 2028 Notes (the “ 2028 Supplemental Indenture ”), the Eighth Supplemental Indenture with respect to the 2030 Notes (the “ 2030 Supplemental Indenture ”) and the Ninth Supplemental Indenture with respect to the 2031 Notes (the “ 2031 Supplemental Indenture ” and, together with the 2027 Supplemental Indenture, the 2028 Supplemental Indenture and the 2030 Supplemental Indenture, the “ Supplemental Indentures ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1124140/000119312526118700/0001193125-26-118700-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.